Reaction
Bleeding Varicose Vein reporting signals
As of the last recalculation, Bleeding Varicose Vein appears in 535 FAERS reports alongside 10 co-occurring drug terms. The strongest observed disproportionality signal is ATEZOLIZUMAB (PRR 76.6).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Atezolizumab | 67 | 76.6 | 76.7 |
| Sofosbuvir | 34 | 71.5 | 71.6 |
| Nevirapine | 15 | 66.5 | 66.6 |
| Bevacizumab | 85 | 31.6 | 31.6 |
| Methimazole | 6 | 30.1 | 30.1 |
| Ribavirin | 45 | 29.6 | 29.7 |
| Sorafenib | 13 | 24.9 | 24.9 |
| Rifaximin | 8 | 15.1 | 15.1 |
| Peginterferon Alfa-2A | 16 | 11.8 | 11.8 |
| Ledipasvir And Sofosbuvir | 4 | 8.1 | 8.1 |